Your new post is loading...
Click here to edit the content
Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Already have an account: Login
Genetic Engineering in the Press by GEG
36.0K views |
+6 today
The Proposed Acquisition Would Combine Sangamo's Ex Vivo Gene Editing Capabilities and TxCell's Treg Expertise and Would Position Sangamo as a Leader in CAR-Treg Development
Initiation of First CAR-Treg Clinical Trial Expected in 2019